PriceTargets.com logo

Avidity Biosciences - RNA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $64.36
  • Forecasted Upside: 102.27%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$31.82 As of 12/20/2024 06:16 PM ET
▲ +0.77 (2.48%)

This chart shows the closing price for RNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Avidity Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RNA

Analyst Price Target is $64.36
▲ +102.27% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Avidity Biosciences in the last 3 months. The average price target is $64.36, with a high forecast of $96.00 and a low forecast of $45.00. The average price target represents a 102.27% upside from the last price of $31.82.

This chart shows the closing price for RNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 11 polled investment analysts is to buy stock in Avidity Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/20/2024HC WainwrightInitiated CoverageBuy$72.00
11/26/2024Royal Bank of CanadaInitiated CoverageOutperform$67.00
11/13/2024Chardan CapitalReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
11/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
10/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
10/30/2024Chardan CapitalBoost TargetBuy ➝ Buy$60.00 ➝ $65.00
10/21/2024TD CowenBoost TargetBuy ➝ Buy$56.00 ➝ $78.00
9/24/2024The Goldman Sachs GroupInitiated CoverageBuy$59.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$96.00 ➝ $96.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$96.00 ➝ $96.00
8/28/2024BarclaysInitiated CoverageOverweight$63.00
8/26/2024Evercore ISILower TargetOutperform ➝ Outperform$54.00 ➝ $53.00
8/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
8/12/2024Evercore ISIBoost TargetOutperform ➝ Outperform$45.00 ➝ $54.00
8/9/2024Chardan CapitalBoost TargetBuy ➝ Buy$45.00 ➝ $60.00
6/13/2024Bank of AmericaBoost TargetBuy ➝ Buy$40.00 ➝ $45.00
6/12/2024Chardan CapitalBoost TargetBuy ➝ Buy$33.00 ➝ $45.00
6/12/2024Evercore ISIBoost TargetOutperform ➝ Outperform$40.00 ➝ $45.00
6/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
5/10/2024Chardan CapitalReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
5/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00
5/3/2024Bank of AmericaInitiated CoverageBuy$40.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00
3/14/2024Cantor FitzgeraldInitiated CoverageOverweight$60.00
2/29/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00
2/29/2024Chardan CapitalReiterated RatingBuy ➝ Buy$23.00
1/3/2024Wells Fargo & CompanyReiterated RatingOverweight ➝ Overweight$50.00
11/29/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00
8/9/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$35.00
8/9/2023Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$30.00
8/9/2023Chardan CapitalLower TargetBuy ➝ Buy$27.00 ➝ $23.00
5/22/2023Evercore ISIUpgradeIn-Line ➝ Outperform$20.00
5/11/2023Wells Fargo & CompanyLower Target$55.00 ➝ $50.00
3/31/2023Credit Suisse GroupLower TargetOutperform$35.00 ➝ $30.00
3/31/2023Chardan CapitalReiterated RatingBuy$27.00
3/1/2023Needham & Company LLCReiterated RatingBuy$35.00
3/1/2023Chardan CapitalReiterated RatingBuy$27.00
3/1/2023Credit Suisse GroupReiterated RatingOutperform$35.00
1/4/2023Wells Fargo & CompanyLower TargetOverweight$60.00 ➝ $55.00
12/14/2022Credit Suisse GroupBoost TargetOutperform$33.00 ➝ $35.00
12/14/2022Raymond JamesBoost TargetStrong-Buy$30.00 ➝ $71.00
11/9/2022Raymond JamesBoost TargetStrong-Buy$29.00 ➝ $30.00
11/9/2022Credit Suisse GroupBoost TargetOutperform$32.00 ➝ $33.00
9/27/2022Needham & Company LLCLower TargetBuy$50.00 ➝ $35.00
9/27/2022Chardan CapitalLower TargetBuy$29.00 ➝ $27.00
7/20/2022Chardan CapitalInitiated CoverageBuy$29.00
7/11/2022Raymond JamesInitiated CoverageStrong-Buy$29.00
12/10/2021Wells Fargo & CompanyReiterated RatingBuy$59.00
12/10/2021Leerink PartnersBoost TargetOutperform$36.00 ➝ $53.00
9/7/2021Evercore ISIInitiated CoverageOutperform$50.00
8/10/2021Credit Suisse GroupLower TargetOutperform$37.00 ➝ $36.00
6/17/2021Needham & Company LLCInitiated CoverageBuy$50.00
5/19/2021Leerink PartnersInitiated CoverageBuy$36.00
7/7/2020Leerink PartnersInitiated CoverageOutperform$36.00
7/7/2020CowenInitiated CoverageOutperform
7/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$60.00
7/7/2020Credit Suisse GroupInitiated CoverageOutperform$34.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.14 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 15 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 7 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 20 very positive mentions
  • 25 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 12 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 24 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 14 very positive mentions
  • 23 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 29 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 29 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Avidity Biosciences logo
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $31.82
Low: $30.85
High: $32.63

50 Day Range

MA: $42.38
Low: $30.70
High: $52.50

52 Week Range

Now: $31.82
Low: $8.49
High: $56.00

Volume

2,906,533 shs

Average Volume

1,316,742 shs

Market Capitalization

$3.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Avidity Biosciences?

The following Wall Street sell-side analysts have issued stock ratings on Avidity Biosciences in the last year: Bank of America Co., Barclays PLC, Cantor Fitzgerald, Chardan Capital, Evercore ISI, HC Wainwright, Needham & Company LLC, Royal Bank of Canada, TD Cowen, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for RNA.

What is the current price target for Avidity Biosciences?

0 Wall Street analysts have set twelve-month price targets for Avidity Biosciences in the last year. Their average twelve-month price target is $64.36, suggesting a possible upside of 102.3%. Cantor Fitzgerald has the highest price target set, predicting RNA will reach $96.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $45.00 for Avidity Biosciences in the next year.
View the latest price targets for RNA.

What is the current consensus analyst rating for Avidity Biosciences?

Avidity Biosciences currently has 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RNA will outperform the market and that investors should add to their positions of Avidity Biosciences.
View the latest ratings for RNA.

What other companies compete with Avidity Biosciences?

Other companies that are similar to Avidity Biosciences include Moderna, Viatris, Summit Therapeutics, Genmab A/S and Dr. Reddy's Laboratories. Learn More about companies similar to Avidity Biosciences.

How do I contact Avidity Biosciences' investor relations team?

Avidity Biosciences' physical mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The biotechnology company's listed phone number is 858-401-7900 and its investor relations email address is [email protected]. The official website for Avidity Biosciences is www.aviditybiosciences.com. Learn More about contacing Avidity Biosciences investor relations.